CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies

被引：21

作者：

Ayed, Ayed O. ^{[1
]}

Chiappella, Annalisa ^{[2
]}

Pederson, Levi ^{[3
]}

Laplant, Betsy R. ^{[3
]}

Congiu, Angela Giovanna ^{[4
]}

Gaidano, Gianluca ^{[5
]}

Spina, Michele ^{[6
]}

Re, Alessandro ^{[7
]}

Cavallo, Federica ^{[8
]}

Musuraca, Gerardo ^{[9
]}

Macon, William R. ^{[10
]}

Witzig, Thomas ^{[1
]}

Vitolo, Umberto ^{[2
]}

Nowakowski, Grzegorz S. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA

[2] Citta Salute & Sci Hosp & Univ, Div Hematol, Turin, Italy

[3] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA

[4] IRCCS San Martino Hosp & Univ, Dept Hematol, Genoa, Italy

[5] Amedeo Avogadro Univ Eastern Piedmont, Div Hematol, Dept Translat Med, Novara, Italy

[6] Natl Canc Inst, Div Med Oncol A, Aviano, Italy

[7] ASST Spedali Civili Brescia, Dept Hematol, Brescia, Italy

[8] Univ Torino, Dept Hematol, Turin, Italy

[9] Ist Sci Romagnolo Studio & Cura Tumori, Dept Hematol, Meldola Fc, Meldola, Italy

[10] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA

来源：

BLOOD CANCER JOURNAL | 2018年 / 8卷

关键词：

B-CELL LYMPHOMA; NON-HODGKINS-LYMPHOMA; NERVOUS-SYSTEM PROPHYLAXIS; STUDY-GROUP DSHNHL; RISK-FACTORS; ELDERLY-PATIENTS; PHASE-II; AGGRESSIVE LYMPHOMA; RITUXIMAB; TRIAL;

D O I：

10.1038/s41408-018-0097-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a devastating event occurring in similar to 5% of patients treated with R-CHOP. We hypothesized that adding lenalidomide to R-CHOP (R2CHOP) may decrease the risk of CNS relapse. We analyzed records for patients with DLBCL from two R2CHOP trials. We assessed variables pertinent to the CNS-International Prognostic Index (CNS-IPI) scoring system and classified patients into groups of low, intermediate, and high risk of CNS relapse. The 2-year CNS relapse rate for each risk group was estimated using the Kaplan-Meier method and compared with reported rates in cohorts treated with contemporary chemoimmunotherapy. A total of 136 patients were included. Mean age was 65 and median follow-up was 48.2 months. 10.3, 71.3, and 18.4% of patients were classified into low, intermediate, and high-risk CNS-IPI groups, respectively. Only one of 136 patients developed CNS relapse, corresponding to an incidence of 0.7% and an estimated 2-year CNS relapse rate of 0.9% for the entire R2CHOP cohort. The estimated 2-year CNS relapse rates for the low, intermediate, and high-risk groups were 0, 0, and 5.0%, respectively. Frontline therapy with R2CHOP in patients with DLBCL is associated with a lower-than-expected rate of CNS relapse.

引用

页数：5

共 24 条

[1] High-dose chemotherapy and autologous stem cell transplantation for secondary central nervous system lymphoma: many are called, but few are chosen [J].